Tenon Medical (TNON) investor relations material

Company overview and business model

• Focuses on medical devices for sacro-pelvic disorders, offering minimally invasive SI Joint fusion systems with FDA clearance since 2018.

• Commercial portfolio includes Catamaran and SImmetry systems, targeting primary, revision, and adjunct SI Joint procedures.

• Acquired assets from SiVantage and SIMPL Medical in August 2025, expanding product offerings.

• Emphasizes innovation in implant design and surgical approach to address low market penetration for SI Joint surgery.

• Operates primarily in the US market, with ongoing clinical studies and regulatory compliance.

Financial performance and metrics

• As of August 10, 2026, public float was $13.2 million, with 606,596 shares held by non-affiliates at $21.75 per share.

• Last reported sale price of common stock was $6.05 per share on August 10, 2026.

• Net tangible book value as of March 31, 2026, was $(3.04) per share; pro forma after offering would be $3.01 per share.

• Immediate dilution to new investors estimated at $3.04 per share if offering is fully subscribed.

• Financial statements include a going concern warning from auditors.

Use of proceeds and capital allocation

• Proceeds intended for commercial expansion, clinician training, sales force growth, distribution network expansion, clinical research, R&D, inventory, marketing, working capital, and general corporate purposes.

• Management retains broad discretion over allocation of funds.